This property candidates irisin as a potential therapeutic target in metabolic diseases, including metabolic syndrome, T2DM, and nonalcoholic fatty liver disease (NAFLD), in which IR plays a major pathogenic role [143]. The gene discussed is FNDC5; the disease is metabolic dysfunction-associated steatotic liver disease.